After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...